 | Up a level |
2018
Griesinger, F., Radke, S., Lueers, A., Deschler-Baier, B., Kimmich, M., Sebastian, M., Schulz, C., Brugger, W., Wiewrodt, R., Pirker, R., Fruh, M., Gautschi, O. and Wolf, J. (2018). Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example. Pneumologie, 72 (11). S. 774 - 782. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
2017
Roeper, J., Lueers, A., Netchaeva, M., Falk, M., Hallas, C., Tiemann, M., Neemann, N., Heukamp, L., Wesseler, C., Wiest, G. H., Ukena, D., Sackmann, S. and Griesinger, F. (2017). Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt1 and ALK1 pts: Results of the NOWEL network. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2016
Menon, R., Mueller, J., Heuckmann, J., Lueers, A., Heukamp, L., Wolf, J. and Griesinger, F. (2016). Discovery of a novel EGFR resistance mutation by capture based NGS following AZD9291 treatment. Oncol. Res. Treat., 39. S. 120 - 121. BASEL: KARGER. ISSN 2296-5262
2015
Griesinger, F., Sebastian, M., Serke, M., Buettner, R., Waller, C., Reinmuth, N., Graeven, U., Lueers, A., Radke, S., Karatas, A., Heukamp, L., Tiemann, M. and Overbeck, T. (2015). Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: Neolntercal. Oncol. Res. Treat., 38. S. 140 - 141. BASEL: KARGER. ISSN 2296-5262